2025
Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Deshmukh S, Wu S, Xiu J, Hong C, Yao S, Sudmeier L, Kalinski P, Chalasani P, Repasky E, Ernstoff M, Leone J, Chumsri S, Graff S, Lustberg M, Sledge G, Kalinsky K, Gandhi S. Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1107-1107. DOI: 10.1200/jco.2025.43.16_suppl.1107.Peer-Reviewed Original ResearchTriple negative breast cancerBreast cancerOverall survivalTumor microenvironmentReal-world overall survivalADRB2 gene expressionNegative breast cancerImmune cell fractionsB2 adrenergic receptorPromote tumor growthMann-Whitney U testHighest survival benefitTriple negative breast cancer samplesKaplan-Meier estimatesSurvival benefitImmunological featuresGene expressionPreclinical modelsImmune characterizationTumor growthMann-WhitneyObservational studyU testADRB2RNA expressionInterferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
Chumsri S, Liu Y, Deshmukh S, Carter J, Joensuu H, Leon-Ferre R, Zahrieh D, Boughey J, Ingle J, Couch F, Roussos Torres E, Lustberg M, Stover D, Sikov W, Partridge A, Carey L, Sledge G, Goetz M, Knutson K, Thompson E. Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data. Journal Of Clinical Oncology 2025, 43: 569-569. DOI: 10.1200/jco.2025.43.16_suppl.569.Peer-Reviewed Original ResearchTriple-negative breast cancerRecurrence-free survivalTumor-infiltrating lymphocytesLocation of tumor-infiltrating lymphocytesOverall survivalSignature scoreInterferon SignalingAssociated with pathologic complete responseTriple-negative breast cancer patientsReal-world overall survivalPathological complete responseResidual cancer burdenTriple-negative breast cancer samplesClinical trial cohortAssociated with significant improvementsClinical outcome dataKaplan-Meier estimatesMann-Whitney UPotential key biomarkersMedian OSComplete responsePCR rateTNBC cohortPrognostic roleImmune desertMHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
Liu Y, Deshmukh S, Ma Y, Carter J, Wu S, Xiu J, Norton N, Ruddy K, Ruddy K, Perez E, Gandhi S, Barreto Coelho P, Lustberg M, Goetz M, Joensuu H, Sledge G, Thompson E, Chumsri S. MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial. Journal Of Clinical Oncology 2025, 43: 570-570. DOI: 10.1200/jco.2025.43.16_suppl.570.Peer-Reviewed Original ResearchTriple-negative BCMHC-I expressionCD8+ T cellsHER2+Overall survivalI expressionBC subtypesBreast cancerMHC-IT cellsHLA-CAssociated with higher immune infiltrationDownregulation of MHC-I expressionFrequency of PD-L1 positivityHLA-AHLA-BT cell inflamed scoreExpression of HLA-AInfiltration of B cellsMHC class I expressionSubtypes of breast cancerMechanisms of immune evasionReal-world overall survivalHormone receptor-positivePD-L1 positivityEvaluation of tumor immune microenvironment in Hispanic and African American breast cancer.
Hsu R, Deshmukh S, Rallos E, Al-zubeidy B, Martynova A, Stewart D, Jayachandran P, Spicer D, Wu S, Xiu J, Sledge G, Gandhi S, Chumsri S, Leone J, Mahtani R, Sandoval Leon A, Lustberg M, Roussos Torres E. Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer. Journal Of Clinical Oncology 2025, 43: 1051-1051. DOI: 10.1200/jco.2025.43.16_suppl.1051.Peer-Reviewed Original ResearchTumor immune microenvironmentPrimary breast cancerCD8+ T cellsBreast cancerT cellsPD-L1Non-Hispanic whitesOverall survivalImmune microenvironmentIFN-gammaInflamed tumor immune microenvironmentAdvanced-stage breast cancerReal-world overall survivalEarly-stage BCImmune cell fractionsM2-like macrophagesMann-Whitney U testAfrican American breast cancerKaplan-Meier estimatesAA tumorsHER2+TMB-highPBC casesBC patientsImmune cellsMultiomic profiling of LRRC15 in triple negative breast cancer (TNBC).
Morgenstern Kaplan D, Deshmukh S, Wu S, Xiu J, Lopes G, Valdes F, King T, George S, Hurley J, Salazar A, Sucre S, Trapani D, Advani P, Jayachandran P, Lustberg M, Sledge G, Barreto Coelho P. Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1098-1098. DOI: 10.1200/jco.2025.43.16_suppl.1098.Peer-Reviewed Original ResearchTriple negative breast cancerCancer-associated fibroblastsImmune cell fractionsH tumorsOverall survivalTumor microenvironmentT cellsHigher expression of immune checkpoint genesAbundance of cancer-associated fibroblastsTNBC heterogeneityExpression of immune checkpoint genesIncreased CAFsT cell inflamed scoreAssociated with better OSCD8+ T cellsInfiltration of B cellsReal-world overall survivalAnalysis of immune cellsFrequency of PIK3CAPositive predictive biomarkerPD-L1 positivityAssociated with poor prognosisImmune checkpoint genesTreatment-related survivalAdverse prognostic biomarkerChemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC).
Gandhi S, Deshmukh S, Wu S, Xiu J, Lesinski G, Paulos C, Czerniecki B, Chalasani P, Yao S, Ernstoff M, Chumsri S, Trapani D, Leone J, Lustberg M, Sledge G, Kalinsky K, Kalinski P. Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1106-1106. DOI: 10.1200/jco.2025.43.16_suppl.1106.Peer-Reviewed Original ResearchTriple negative breast cancerImmune checkpoint inhibitorsTumor mutational burdenTumor microenvironmentCXCR3 expressionBreast cancerHER2+Overall survivalPredictive biomarkersHigher expression of immune checkpoint genesExpression of immune checkpoint genesImmune checkpoint inhibitor pembrolizumabT cell inflamed scoreImmune checkpoint inhibitor efficacyAssociated with longer survivalReal-world overall survivalCognate receptor CXCR3Enhance ICI efficacyPD-L1 positivityT cell infiltrationImmune checkpoint genesAggressive breast cancerNegative breast cancerTumor microenvironment characteristicsImmune cell fractionsComprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
Bustos M, Deshmukh S, Samec T, Wu S, Xiu J, Advani P, Jayachandran P, Mahtani R, Graff S, Lustberg M, Grumley J, Sledge G, Hoon D. Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1114-1114. DOI: 10.1200/jco.2025.43.16_suppl.1114.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall survivalTumor microenvironmentBreast cancerManagement of triple-negative breast cancerInfiltration of NK cellsImmune suppressive tumor microenvironmentReal-world overall survivalSuppressive tumor microenvironmentPercentage of younger patientsDrug efflux genesImmune cell fractionsStem cell genesMann-Whitney U testKaplan-Meier estimatesL groupImmune checkpointsShorter OSNK cellsTNBC patientsTherapy resistanceTherapeutic optionsYounger patientsClinical outcomesFisher's exactTrial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
Huppert L, Ellisen L, Anders C, Isaacs C, Santa-Maria C, Anampa J, DeMichele A, Balic M, Specht J, Lustberg M, Wolff A, Krop I, Rugo H. Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067). Journal Of Clinical Oncology 2025, 43: tps1137-tps1137. DOI: 10.1200/jco.2025.43.16_suppl.tps1137.Peer-Reviewed Original ResearchMetastatic breast cancerReal-world overall survivalProgression free survivalHER2-negative metastatic breast cancerMetastatic triple negative breast cancerStandard of careAntibody-drug conjugatesDisease control rateDuration of responseOverall survivalBreast cancerPatient-reported outcomesFree survivalHER2 negative metastatic breast cancerTreatment strategiesHormone receptor-positive/HER2-negativeNegative metastatic breast cancerTriple negative breast cancerEffective new treatment strategyPhase III clinical trialsRegistry study of patientsKaplan-Meier methodNegative breast cancerIII clinical trialsNew treatment strategiesStreamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
Zeidan A, Yu R, Wang Y, Lan Z, Grinblatt D, Elsouda D, Spalding J, Block A, Touya M, Walker M, Pandya B. Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. Acta Haematologica 2025, 1-12. PMID: 40228486, PMCID: PMC12112888, DOI: 10.1159/000545384.Peer-Reviewed Original ResearchAcute myeloid leukemiaReal-world overall survivalAcute myeloid leukemia diagnosisReal-world time to next treatmentTreatment patternsFLT3-TKIMyeloid leukemiaClinical outcomesMedian real-world overall survivalTime to next treatmentClinical outcomes of patientsFLT3 tyrosine kinase inhibitorsReal-world treatment patternsAcute myeloid leukemia patientsFMS-like tyrosine kinase 3R/R AML patientsHigh-intensity chemotherapyOutcomes of patientsRetrospective cohort studyTyrosine kinase 3Retrospective longitudinal studyFirst relapseOverall survivalAML patientsFLT3 mutationsReal-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents
Chiang A, Madison R, Assaf Z, Fine A, Cao Y, Gjoerup O, Huang Y, Jin D, Hughes J, Antic V, Young A, Fabrizio D, Shames D, Maund S, Exarchos A, Lakhanpal S, Zuniga R, Pasquina L, Schulze K. Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents. JTO Clinical And Research Reports 2025, 100829. DOI: 10.1016/j.jtocrr.2025.100829.Peer-Reviewed Original ResearchSmall cell lung cancerReal-world progression-free survivalCirculating tumor DNAReal-world overall survivalCirculating tumor DNA dynamicsTumor fractionTumor response to immunotherapyLung cancer treated with chemotherapyCancer treated with chemotherapyProgression-free survivalResponse to immunotherapyCell lung cancerNon-small cellTumor imagingChemo-ImmunotherapyTumor responseOverall survivalTherapy initiationTumor DNAExploratory cohortTargeted therapyCtDNA quantificationTargeted agentsTreatment modalitiesTreatment regimens
2023
Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy
Bair S, Narkhede M, Frosch Z, Chong E, Ermann D, Isufi I, Awan F, Chavez J, Bosma G, Abbott D. Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy. Blood 2023, 142: 68. DOI: 10.1182/blood-2023-187113.Peer-Reviewed Original ResearchReal-world progression-free survivalReal-world overall survivalMultivariate Cox regression analysisR-CHOPAlternative regimensAge 70Partial responseTreatment intensityComplete responseMedian ageElderly ptsMedian Charlson Comorbidity Index scoreMedian real-world overall survivalCharlson Comorbidity Index scoreHigh-risk IPI scoreLarge real-world studyAnthracycline-based chemoimmunotherapyHigh-risk IPIComorbidity Index scoreFirst-line therapyProgression-free survivalKaplan-Meier methodCox regression analysisLong-term outcomesLog-rank testSurvival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply